Immune cells re-engineered to fight rare disease
NCT ID NCT07298590
First seen Jan 06, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This early-phase study tests a new treatment called KN5601, made from a person's own immune cells (NK cells) that are modified to target two proteins (CD19 and BCMA) involved in IgG4-related disease (IgG4-RD). The goal is to see if it is safe and can help people whose disease has come back or not responded to standard treatments. Up to 18 adults aged 18-70 with active IgG4-RD will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGG4 RELATED DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changhai Hospital
Shanghai, 200433, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.